A Phase 3 interventional study of Pembrolizumab and Placebo for pembrolizumab in Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 227 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing pembrolizumab in Ovarian Neoplasms — 7 open to participants now, 13 under way, 2 of them phase 3. pembrolizumab · Ovarian Neoplasms.
Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, this one has the largest enrollment, is one of 7 that started in 2018, is one of 2 in phase 3, and was the 21st registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →7 of the 35 studies testing pembrolizumab in Ovarian Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Obstetrics & Gynecology Hospital of Fudan University · Sites in China
Ages 18–75 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–70
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Sheba Medical Center · Sites in Israel
Ages 18+ · Women only
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 30 · Phase 3 3
First in 2010; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,367 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 38 across the 35 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Ovarian Neoplasms by Merck & Co., Inc: 6 open now, 7 under way, 5 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 27 studies in Ovarian Neoplasms by Merck & Co., Inc, this one has the largest enrollment of the 25 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 3, and was the 17th registered.
Merck & Co., Inc’s Ovarian Neoplasms studies by the year they started, since 1999.
2 of the studies testing pembrolizumab in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06083844M.D. Anderson Cancer CenterPhase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | 2027-09-30 |
| NCT07261683Obstetrics & Gynecology Hospital of Fudan UniversityPhase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 27 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.
The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1) positive tumors (Combined Positive Score [CPS]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1 positive tumors (CPS≥10) and in all participants.
Following a lead-in period during which all participants receive a single 3-week cycle of carboplatin/paclitaxel*, participants will be randomly assigned in to one of three treatment arms, and will receive carboplatin/paclitaxel* for 5 cycles plus:
Placebo for Pembrolizumab + Placebo for Olaparib
At Investigator's discretion and prior to participant randomization, one of the following carboplatin/paclitaxel regimens is to be selected:
Docetaxel may be considered for participants who experience either a severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel only after consultation with the Sponsor. The recommended dose as determined by the Scottish Gynaecological Cancer Trials Group is Docetaxel 75 mg/m\^2 Q3W plus carboplatin AUC 5 Q3W.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Olaparib · Biological: Bevacizumab · Drug: Docetaxel
Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Placebo for olaparib · Biological: Bevacizumab · Drug: Docetaxel
Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
Drug: Placebo for pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Placebo for olaparib · Biological: Bevacizumab · Drug: Docetaxel
IV infusion
Also known as: MK-3475, KEYTRUDA®
IV infusion
Also known as: normal saline or dextrose
IV infusion
Also known as: PARAPLATIN®
IV infusion
Also known as: TAXOL®
Oral tablet
Also known as: MK-7339, LYNPARZA®
Oral tablet
IV infusion
Also known as: AVASTIN®
IV infusion
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)
PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for participants with PD-L1 positive tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants
PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10)
OS is defined as the time from the date of randomization to death due to any cause. The OS is reported for all participants with PD-L1 positive tumors (CPS≥10). The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
OS in All Participants
OS is defined as the time from the date of randomization to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10)
PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for participants with PD-L1 positive (CPS≥10) tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 66 months
PFS Per RECIST 1.1 as Assessed by BICR in All Participants
PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 66 months
PFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10)
PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for participants with PD-L1 positive tumors (CPS≥10). PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
PFS2 Following Discontinuation of Study Treatment as Assessed by the Investigator in All Participants
PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for all participants. PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) (GHS/QoL) Combined Score
The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. Change from baseline to Week 45 in EORTC QLQ-C30 Items 29 and 30 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).
Time frame: Baseline and week 45
Mean Change From Baseline in Abdominal and Gastrointestinal (Abdominal/GI) Symptoms Score Using the EORTC Quality of Life Questionnaire-Ovarian Cancer (QLQ-OV28) Abdominal/GI Symptom Scale
Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. Change from baseline to Week 45 in EORTC QLQ-OV28 Items 31-36 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).
Time frame: Baseline and week 45
Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. TTD is defined as the time from the first EORTC QLQ-C30 Items 29 and 30 combined scores to deterioration (defined as ≥10-point decrease in GHS/QoL score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 31 months
Time to Deterioration (TTD) of Abdominal/GI Symptoms Using EORTC QLQ-OV28
Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. TTD is defined as the time from the first EORTC QLQ-OV28 questions 31-36 combined scores to deterioration (defined as ≥10-point decrease in abdominal/GI symptoms score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 31 months
Time to First Subsequent Anti-cancer Treatment (TFST) in Participants With PD-L1 Positive Tumors (CPS≥10)
TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Time to First Subsequent Anti-cancer Treatment (TFST) in All Participants
TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Time to Second Subsequent Anti-cancer Treatment (TSST) in Participants With PD-L1 Positive Tumors (CPS≥10)
TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Time to Second Subsequent Anti-cancer Treatment (TSST) in All Participants
TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Time to Discontinuation of Study Treatment or Death (TDT) in Participants With PD-L1 Positive Tumors (CPS≥10)
TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Time to Discontinuation of Study Treatment or Death (TDT) in All Participants
TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.
Time frame: Up to approximately 67 months
Pathological Complete Response (pCR) Rate in Participants With PD-L1 Positive Tumors (CPS≥10)
pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no).
Time frame: Up to approximately 21 months
Pathological Complete Response (pCR) Rate in All Participants
pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no) and PD-L1 status (CPS \<10 versus CPS\>=10).
Time frame: Up to approximately 26 months
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 73 months (anticipated)
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.
Time frame: Up to approximately 6 years (anticipated)
| Milestone | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Started | 455 | 458 | 454 |
| Treated | 452 | 456 | 454 |
| Completed | 0 | 0 | 0 |
| Not completed | 455 | 458 | 454 |
| Withdrew: Death | 232 | 242 | 229 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 7 | 4 | 3 |
| Withdrew: Ongoing in study | 216 | 212 | 221 |
PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for participants with PD-L1 positive tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10) | 23.9 (21.0 to 30.2) | 17.3 (15.2 to 19.4) | 15.2 (12.5 to 17.2) |
PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants | 22.2 (18.8 to 24.7) | 15.2 (13.6 to 16.4) | 14.6 (12.7 to 16.3) |
OS is defined as the time from the date of randomization to death due to any cause. The OS is reported for all participants with PD-L1 positive tumors (CPS≥10). The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10) | 50.2 (43.9 to NA) | 56.4 (42.4 to NA) | 51.6 (41.8 to NA) |
OS is defined as the time from the date of randomization to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| OS in All Participants | 47.7 (42.3 to 54.9) | 44.2 (38.1 to 52.2) | 47.1 (41.7 to 60.9) |
PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for participants with PD-L1 positive (CPS≥10) tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10) | 42.0 (27.2 to 51.9) | 20.3 (17.3 to 27.4) | 22.1 (15.4 to 29.5) |
PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| PFS Per RECIST 1.1 as Assessed by BICR in All Participants | 30.1 (24.0 to 37.3) | 19.0 (16.6 to 22.2) | 20.8 (16.9 to 25.3) |
PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for participants with PD-L1 positive tumors (CPS≥10). PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| PFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10) | 41.1 (32.3 to 52.1) | 34.1 (29.0 to 41.2) | 29.9 (25.3 to 37.6) |
PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for all participants. PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| PFS2 Following Discontinuation of Study Treatment as Assessed by the Investigator in All Participants | 33.1 (29.9 to 38.5) | 27.8 (26.0 to 32.5) | 28.9 (25.4 to 34.2) |
The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. Change from baseline to Week 45 in EORTC QLQ-C30 Items 29 and 30 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).
| Score on a Scale | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| cLDA model using Carboplatin+Paclitaxel+Pembrolizumab+Olaparib and Carboplatin+Paclitaxel arms | 0.45 (-1.62 to 2.52) | — | 0.18 (-1.87 to 2.24) |
| cLDA model using Carboplatin+Paclitaxel+Pembrolizumab and Carboplatin+Paclitaxel arms | — | -0.49 (-2.63 to 1.65) | 0.61 (-1.48 to 2.70) |
Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. Change from baseline to Week 45 in EORTC QLQ-OV28 Items 31-36 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).
| Score on a Scale | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| cLDA model using Carboplatin+Paclitaxel+Pembrolizumab+Olaparib and Carboplatin+Paclitaxel arms | -2.63 (-4.40 to -0.85) | — | -2.77 (-4.54 to -1.00) |
| cLDA model using Carboplatin+Paclitaxel+Pembrolizumab and Carboplatin+Paclitaxel arms | — | -2.66 (-4.50 to -0.82) | -2.58 (-4.38 to -0.79) |
The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. TTD is defined as the time from the first EORTC QLQ-C30 Items 29 and 30 combined scores to deterioration (defined as ≥10-point decrease in GHS/QoL score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. TTD is defined as the time from the first EORTC QLQ-OV28 questions 31-36 combined scores to deterioration (defined as ≥10-point decrease in abdominal/GI symptoms score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to Deterioration (TTD) of Abdominal/GI Symptoms Using EORTC QLQ-OV28 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to First Subsequent Anti-cancer Treatment (TFST) in Participants With PD-L1 Positive Tumors (CPS≥10) | 29.3 (24.0 to 33.8) | 22.2 (17.7 to 25.4) | 17.7 (14.1 to 21.4) |
TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to First Subsequent Anti-cancer Treatment (TFST) in All Participants | 24.9 (22.0 to 29.5) | 18.2 (16.8 to 21.0) | 17.2 (15.3 to 19.0) |
TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to Second Subsequent Anti-cancer Treatment (TSST) in Participants With PD-L1 Positive Tumors (CPS≥10) | 43.9 (33.5 to 52.5) | 36.3 (31.9 to 42.8) | 32.3 (27.5 to 39.2) |
TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to Second Subsequent Anti-cancer Treatment (TSST) in All Participants | 34.7 (31.3 to 40.4) | 31.3 (28.1 to 34.2) | 30.9 (27.2 to 35.1) |
TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to Discontinuation of Study Treatment or Death (TDT) in Participants With PD-L1 Positive Tumors (CPS≥10) | 18.9 (14.9 to 22.4) | 15.3 (12.6 to 17.3) | 15.3 (13.0 to 17.3) |
TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.
| Months | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Time to Discontinuation of Study Treatment or Death (TDT) in All Participants | 17.7 (15.7 to 19.5) | 14.1 (12.4 to 15.4) | 15.2 (13.6 to 16.6) |
pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no).
| Percentage of Participants | Pooled Carboplatin+Paclitaxel+Pembrolizumab+Olaparib, and Carboplatin+Paclitaxel+Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|
| Pathological Complete Response (pCR) Rate in Participants With PD-L1 Positive Tumors (CPS≥10) | 9.8 (5.8 to 15.2) | 4.5 (1.2 to 11.1) |
pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no) and PD-L1 status (CPS \<10 versus CPS\>=10).
| Percentage of Participants | Pooled Carboplatin+Paclitaxel+Pembrolizumab+Olaparib, and Carboplatin+Paclitaxel+Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|
| Pathological Complete Response (pCR) Rate in All Participants | 5.9 (3.6 to 9.0) | 2.3 (0.6 to 5.9) |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.
Results for this outcome have not been posted.
Collected over Up to approximately 67 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 237/455 (52.1%) | 205/452 (45.4%) | 445/452 (98.5%) |
| Carboplatin + Paclitaxel + Pembrolizumab | 243/458 (53.1%) | 179/456 (39.3%) | 442/456 (96.9%) |
| Carboplatin + Paclitaxel | 229/454 (50.4%) | 122/454 (26.9%) | 445/454 (98%) |
| Event | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 19/452 | 16/456 | 9/454 |
| PyrexiaGeneral disorders | 15/452 | 7/456 | 4/454 |
| Urinary tract infectionInfections and infestations | 14/452 | 7/456 | 9/454 |
| COVID-19Infections and infestations | 9/452 | 2/456 | 3/454 |
| Intestinal obstructionGastrointestinal disorders | 8/452 | 9/456 | 6/454 |
| PneumoniaInfections and infestations | 7/452 | 8/456 | 1/454 |
| Small intestinal obstructionGastrointestinal disorders | 7/452 | 7/456 | 7/454 |
| AnaemiaBlood and lymphatic system disorders | 6/452 | 5/456 | 4/454 |
| IleusGastrointestinal disorders | 6/452 | 6/456 | 4/454 |
| COVID-19 pneumoniaInfections and infestations | 6/452 | 4/456 | 2/454 |
| Event | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 270/452 | 212/456 | 205/454 |
| NauseaGastrointestinal disorders | 227/452 | 187/456 | 150/454 |
| NeutropeniaBlood and lymphatic system disorders | 170/452 | 138/456 | 147/454 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 136/452 | 142/456 | 139/454 |
| DiarrhoeaGastrointestinal disorders | 121/452 | 138/456 | 94/454 |
| AlopeciaSkin and subcutaneous tissue disorders | 123/452 | 114/456 | 131/454 |
| ConstipationGastrointestinal disorders | 121/452 | 122/456 | 104/454 |
| FatigueGeneral disorders | 120/452 | 115/456 | 85/454 |
| AstheniaGeneral disorders | 116/452 | 97/456 | 70/454 |
| VomitingGastrointestinal disorders | 114/452 | 81/456 | 70/454 |
| Age, Continuous(Years) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel | Total |
|---|---|---|---|---|
| Mean | 60.4 ± 10.6 | 59.8 ± 11.0 | 59.3 ± 11.6 | 59.8 ± 11.1 |
| Sex: Female, Male(Participants) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel | Total |
|---|---|---|---|---|
| Female | 455 | 458 | 454 | 1367 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel | Total |
|---|---|---|---|---|
| Hispanic or Latino | 45 | 41 | 45 | 131 |
| Not Hispanic or Latino | 410 | 415 | 407 | 1232 |
| Unknown or Not Reported | 0 | 2 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin + Paclitaxel | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 0 | 5 |
| Asian | 77 | 73 | 83 | 233 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 4 | 4 | 15 |
| White | 360 | 367 | 357 | 1084 |
| More than one race | 10 | 8 | 9 | 27 |
| Unknown or Not Reported | 0 | 2 | 1 | 3 |
Showing the first 100 of 227 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Dec 2018 to primary completion in Aug 2024, 68 months.
Results were first posted in Sep 2025, 1 year after primary completion.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 68 months is above that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pembrolizumab · Olaparib